News

• Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
  01/20/2021 / 13:50 - GlobeNewswire
•  
• Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
  01/15/2021 / 20:17 - GlobeNewswire
•  
• Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
  01/13/2021 / 15:20 - GlobeNewswire
•  
• An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
  01/08/2021 / 11:45 - GlobeNewswire
•  
• BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
  01/07/2021 / 20:15 - GlobeNewswire
•  
• BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference
  01/05/2021 / 12:00 - GlobeNewswire
•  
• Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
  01/04/2021 / 20:00 - GlobeNewswire
•  
• Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
  12/29/2020 / 19:10 - GlobeNewswire
•  
• Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
  12/23/2020 / 13:44 - GlobeNewswire
•  
• Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
  12/23/2020 / 13:02 - GlobeNewswire
•  
• BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program
  12/21/2020 / 20:10 - GlobeNewswire
•  
• Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
  12/21/2020 / 20:05 - GlobeNewswire
•  
• Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
  12/21/2020 / 15:17 - GlobeNewswire
•  
• BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine
  12/16/2020 / 09:00 - GlobeNewswire
•  
• Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
  12/14/2020 / 12:00 - GlobeNewswire